Skip to content

Antipsychotic Polypharmacy: Prevalence, Background and Consequences

Antipsychotic Polypharmacy: Prevalence, Background and Consequences

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00541398
Enrollment
222
Registered
2007-10-10
Start date
2008-01-31
Completion date
2009-10-31
Last updated
2009-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

Antipsychotic polypharmacy, Schizophrenia, Implementation of clinical guidelines

Brief summary

The primary purpose of the study is to investigate whether an intensive educational intervention can reduce the use of antipsychotic polypharmacy. It is hypothesised that the use of antipsychotic polypharmacy is, in some degree, dependent on non-patient related factors.

Detailed description

Several surveys have shown a high prevalence of antipsychotic polypharmacy (concomitant prescription of at least 2 different antipsychotics) among patients with schizophrenia even though international guidelines recommend monotherapy. From register data areas with differences in the prevalence of antipsychotic polypharmacy will be identified. Two high prevalence areas will be randomized to either control or intervention area. In the intervention area an intensive educational intervention consisting of outreach visits with a multifaceted approach will be carried out with the duration of 1 year. Differences in health staff related factors such as knowledge and attitude towards clinical guidelines will be assessed with a questionnaire before and after the intervention in the intervention area as well as in the low prevalence area at baseline. Medical records data describing the use of antipsychotic polypharmacy will be collected. With register data health economic issues will be assessed.

Interventions

BEHAVIORALImplementation of guideline

Outreach visits with interactive education for health staff

Sponsors

National Board of Health, Denmark
CollaboratorOTHER_GOV
Glostrup University Hospital, Copenhagen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* The intervention is not aimed directly to the patients but their health care providers. * Patients with schizophrenia (F2\* diagnosis according to ICD-10) taking antipsychotic medication and their health care providers in the specified areas will enter the study: * The patients will enter with data from their medical record, register data and a few exploring interviews while the health staff will enter with their questionnaire data.

Design outcomes

Primary

MeasureTime frame
Prevalence of antipsychotic polypharmacy1 year

Secondary

MeasureTime frame
Questionnaire assessment of non-patient related factors. Medical records data. Cost-effectiveness analysis.1 year

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026